CastleArk Alternatives’s DexCom DXCM Stock Holding History

CastleArk Alternatives’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-236,180	Closed	-$32.3M	–	91
2021 Q3	$32.3M	Buy	+236,180	New	+$29.8M	1.23%	22

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CastleArk Alternatives's DXCM Position: Q4 2021 in Review

CastleArk Alternatives sold out of DexCom (DXCM) in Q4 2021, closing a stake of 236,180 shares — an estimated $32.3M sold.

CastleArk Alternatives first reported a position in DXCM in Q3 2021 and held it in 1 quarter. The position peaked at $32.3M in Q3 2021. 930 funds tracked by Wall St. Rank hold DXCM as of Q4 2021.

CastleArk Alternatives reported no remaining DexCom position as of Q4 2021 after selling out during the quarter.
CastleArk Alternatives sold 236,180 DexCom shares in Q4 2021, an estimated $32.3M.
CastleArk Alternatives first reported a position in DexCom in Q3 2021 and held it in 1 quarter.
CastleArk Alternatives's DexCom position peaked at $32.3M in Q3 2021.
930 funds tracked by Wall St. Rank held DexCom as of Q4 2021.

Based on CastleArk Alternatives's 13F filing for Q4 2021, filed 18 Feb 2022.